Can a vaccine control high blood pressure?

The Chicago Sun-Times profiles Cytos' work on a new blood pressure vaccine. Just like new development work being done on vaccines for cancer, asthma and psoriasis, the trick is to identify a protein that plays a role in the disease and make it look like a virus. Early human data has backed Cytos' work in the area, demonstrating that its vaccine is safe and generated a potent immune response. Over a 12-week period, treatment provided in a 72-patient study reduced systolic pressure by 5.6 millimeters and diastolic pressure dropped 5.6 millimeters.

There are skeptics, though. Some say that any immune response to a vaccine could be short-lived, requiring regular boosters. Others wonder about the potential unexpected dangers involved in blocking a protein.

- read the article in the Chicago Sun-Times

Related Articles:
Cytos vaccine offers radically new approach. Report
Novartis, Cytos inks $500M anti-smoking vaccine pact. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.